IQVIA Holdings Inc.: Clinical Trials and AI Enablement As A Major Growth Catalyst!

On the positive side, the company delivered top and bottom-line numbers either on or slightly above the expectations. The favorable demand for the industry continued to surge as IQVIA’s revenue grew by 6%. The clinical side of the business, in particular, saw solid demands from R&DS clients, which boosted their backlog to a new record, growing almost 8% compared to the prior year. A notable achievement was the net new bookings for the quarter which was approximately $2.6 billion. This showcased a strong quarterly book-to-bill of 1.23 despite a substantial cancellation in the CNS area. IQVIA also continued its strategic partnerships and secured contracts with various clients, consequently broadening its market reach.